GSK's India unit Q3 profit up 9% as input costs slump, op revenue fell 1.7%

GlaxoSmithKline Pharmaceuticals Ltd, the Indian unit of UK's GSK plc, reported a 9.5% rise in profit, in line with analysts' estimates, as a sharp drop in input costs more than offset revenue decline

BENGALURU (Reuters) - GlaxoSmithKline Pharmaceuticals Ltd, the Indian unit of UK's GSK plc, reported a 9.5% rise in third-quarter profit on Tuesday, in line with analysts' estimates, as a sharp drop in input costs more than offset a revenue decline.

The Mumbai-based company, said consolidated net profit rose to 1.65 billion rupees ($20 million) in the three months ended Dec. 31, from 1.50 billion rupees a year ago.

Analysts, on average, were also expecting a profit of 1.65 billion rupees, according to Refinitiv IBES data.

Input costs for the company, which makes the Augmentin antibiotic and T-bact oinments to fight bacterial infections, slumped 61.2% to 470.1 million rupees.

Consolidated revenue from operations, however, fell 1.7% to 8.02 billion rupees.

The company's shares settled 0.2% higher at 1,240.15 rupees ahead of the results, while the Nifty pharma index ended flat.

Last week, GSK beat fourth-quarter profit and sales forecasts and unveiled an upbeat guidance for 2023. ($1 = 82.7090 Indian rupees)

 

(Reporting by Rama Venkat in Bengaluru; Editing by Savio D'Souza)